Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)”

作者：D. Oh, Aiwu Ruth He, S. Qin, L. Chen, T. Okusaka, A. Vogel, J.W. Kim, T. Suksombooncharoen, M.A. Lee, M. Kitano, H.A. Burris, M. Bouattour, S. Tanasa, R.E. Zaucha, A. Avallone, J.E. Cundom, N. Rokutanda, M. Żotkiewicz, G.J. Cohen, J.W. Valle · 发表于：Annals of Oncology · 年份：2023 · DOI：10.1016/j.annonc.2023.02.001 · 被引用次数：1 · 研究领域：Cholangiocarcinoma and Gallbladder Cancer Studies、Gallbladder and Bile Duct Disorders、Oral and gingival health research